Biosimilar contract manufacturing market seen reaching $20.35 billion by 2030
The biosimilar contract manufacturing market is projected to grow from $9.94 billion in 2025 to $20.35 billion by 2030, as drugmakers outsource production to specialized manufacturers and demand rises for lower-cost biologics. North America leads now, while Asia-Pacific is expected to grow fastest.
Why it matters: - Biosimilar contract manufacturing is becoming a bigger part of how biologic medicines are made and delivered. - The market growth reflects pressure on drugmakers to lower treatment costs while keeping production compliant, scalable and faster to market. - Rising demand for biosimilar insulin and other biologics could improve access to therapies for chronic diseases.
What happened: - The Business Research Company published its Biosimilar Contract Manufacturing Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 20, 2026. - The report says the market will rise from $9.94 billion in 2025 to $11.49 billion in 2026. - The report projects the market will reach $20.35 billion by 2030. - The forecast implies a 15.7% compound annual growth rate from 2025 to 2026 and a 15.4% CAGR through 2030. - A free sample of the report is available here. - The full report is available here.
The details: - Biosimilar contract manufacturing means outsourcing biosimilar production to third-party manufacturers with specialized facilities, technical expertise and regulatory knowledge. - Biosimilars are biologic medicines designed to be highly similar in safety, efficacy and quality to approved reference biologics. - Contract manufacturing helps biopharmaceutical firms reduce costs, maintain regulatory compliance and shorten time to market. - The report cites patent expirations on reference biologics, early biosimilar development programs, expanding contract manufacturing partnerships, improved regulatory guidance and rising chronic disease prevalence as major 2025-to-2026 growth drivers. - The report cites a surge in biosimilar approvals worldwide, pressure to lower biologic treatment costs, expanding biosimilar pipelines, investment in large-scale manufacturing and process optimization advances as drivers through 2030. - Forecast trends include more outsourcing of biosimilar production, greater demand for cost-efficient manufacturing platforms, increased focus on analytics and quality control, broader use of mammalian cell-based manufacturing and stronger regulatory compliance. - North America led the market in 2025 because of its advanced healthcare infrastructure and regulatory environment. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics, key technology analysis and future trend analysis.
Between the lines: - The market story is less about one product category and more about how biologics manufacturing is shifting toward specialized outsourcing. - Diabetes is one of the clearest demand signals because the disease drives long-term treatment needs and recurring production requirements. - The NHS said in June 2024 that 3,615,330 patients registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022. - That kind of disease burden increases the need for scalable, lower-cost biologic supply chains.
What's next: - More biosimilar outsourcing is expected as drugmakers expand pipelines and seek manufacturing partners with advanced regulatory and quality capabilities. - The fastest growth is likely to come from Asia-Pacific as healthcare investment rises and emerging markets demand more affordable biologics. - Large-scale manufacturing capacity and process optimization will be key battlegrounds for contract manufacturers competing for biosimilar work.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Economic News Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.